Browse News
Filter News
Found 59 articles
-
Sol-Gel Reports Full-Year 2023 Financial Results and Corporate Developments
3/13/2024
Sol-Gel Technologies, Ltd. is conducting a phase 3 clinical trial of SGT-610, an Orphan Drug candidate with the potential to be the first therapy for preventing new basal cell carcinomas in Gorlin syndrome and partnered with Galderma to commercialize two approved large-category dermatology products, TWYNEO® and EPSOLAY®, in the U.S, announced financial results for the full year ended December 31st, 2023 and provided a corporate update.
-
BridgeBio Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update
2/22/2024
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio or the Company) today reported its financial results for the fourth quarter and full year ended December 31, 2023, and provided an update on the Company’s operations.
-
Sol-Gel Technologies Screens First Patient for SGT-610 Phase 3 Study
11/30/2023
Sol-Gel Technologies, Ltd. (Nasdaq: SLGL) (“Sol-Gel”) today announced that it has begun Phase 3 testing of SGT-610 (patidegib gel, 2%) for Gorlin syndrome with the first patient screened.
-
Sol-Gel Technologies Ltd to Host Virtual KOL Event on Gorlin Syndrome and the Upcoming Phase 3 Trial for SGT-610
11/28/2023
Sol-Gel Technologies, Ltd. (Nasdaq: SLGL) (“Sol-Gel”), a dermatology company leveraging innovative approaches to develop pioneering treatments for patients with severe skin conditions, and with two approved large-category dermatology products, TWYNEO® and EPSOLAY®, today announced it will host a virtual KOL event on Wednesday, December 6, 2023 at 12:00 PM ET.
-
BridgeBio Pharma Reports Third Quarter 2023 Financial Results and Business Update
11/2/2023
BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, reported its financial results for the third quarter ended September 30, 2023, and provided an update on the Company’s operations.
-
Sol-Gel Technologies Reports Second Quarter 2023 Financial Results and Provides Corporate Update
8/10/2023
Sol-Gel today announced financial results for the second quarter ended June 30, 2023 and provided a corporate update.
-
BridgeBio Pharma Reports Second Quarter 2023 Financial Results and Business Update
8/3/2023
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio or the Company), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today reported its financial results for the second quarter ended June 30, 2023 and provided an update on the Company’s operations.
-
Sol-Gel Technologies Reports First Quarter 2023 Financial Results and Provides Corporate Update
5/12/2023
Sol-Gel Technologies, Ltd., a dermatology company with two innovative dermatology products, EPSOLAY and TWYNEO, that were launched in the U.S., SGT-610, which is Phase 3-ready, and an earlier-stage SGT-210, announced financial results for the first quarter ended March 31, 2023 and provided a corporate update.
-
BridgeBio Pharma Reports First Quarter 2023 Financial Results and Business Update
5/4/2023
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio or the Company), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today reported its financial results for the first quarter ended March 31, 2023 and provided an update on the Company’s operations.
-
Jasper Therapeutics Appoints David Hinds as Senior Vice President, Development Operations
4/10/2023
Jasper Therapeutics, Inc. announced the appointment of David Hinds, as the Company’s Senior Vice President, Development Operations.
-
Sol-Gel Reports Full-Year 2022 Financial Results and Corporate Developments
3/10/2023
Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company with two innovative dermatology products that were launched in the U.S. and an innovative pipeline, today announced financial results for the full year ended December 31, 2022 and provided a corporate update.
-
BridgeBio Pharma Reports Fourth Quarter and Full Year 2022 Financial Results and Business Update
2/23/2023
BridgeBio Pharma, Inc. today reported its financial results for the fourth quarter and full year ended December 31, 2022 and provided an update on the Company’s operations.
-
Sol-Gel Acquires Patidegib, a Phase 3, FDA-Breakthrough-Designated Orphan Product Candidate to Pursue Potential Market of Over $300 Million
1/27/2023
Sol-Gel Technologies, Ltd. announced today the acquisition of topically-applied patidegib, a hedgehog signaling pathway blocker, for the treatment of Gorlin syndrome from PellePharm, Inc.
-
BridgeBio Pharma, Inc. Reports Third Quarter 2022 Financial Results and Business Update
11/3/2022
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio or the Company), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today reported its financial results for the third quarter ended September 30, 2022 and provided an update on the Company’s operations.
-
Simcha Therapeutics Accelerates Growth with Key Leadership Appointments, Expanded Research and Option Agreement with Yale School of Medicine
8/16/2022
Simcha Therapeutics today announced the appointment of Sanuj Ravindran, M.D., as chief executive officer and director, and Jake Bauer as an independent member and chair of its board of directors.
-
BridgeBio Pharma, Inc. Reports Second Quarter 2022 Financial Results and Business Update
8/4/2022
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio or the Company), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today reported its financial results for the second quarter ended June 30, 2022, and provided an update on the Company’s operations.
-
NFlection Therapeutics Appoints William Hodder as CEO and Expands Leadership Team to Accelerate Development of Targeted Treatments for Rare Diseases
10/18/2021
NFlection Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing novel drug candidates for rare RASopathies, today announced that it has appointed William Hodder as CEO.
-
ASLAN Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update
5/11/2021
- Next data readout for ASLAN004 in the treatment of patients with moderate to severe atopic dermatitis anticipated in the third quarter of 2021 - Phase 2b clinical trial for ASLAN004 expected to initiate in the second half of 2021
-
BridgeBio Pharma, Inc. Reports First Quarter 2021 Financial Results And Business Update
5/6/2021
– Received U.S. Food and Drug Administration (FDA) approval for NULIBRY™ (fosdenopterin) for injection as the first therapy to reduce the risk of mortality in patients with molybdenum cofactor deficiency ( MoCD) Type A – Reported pr oof-of-concept data of encaleret in Autosomal Dominant Hypocalcemia Type 1 (ADH1) –
-
Hedgehog Pathway Inhibitors Market: Basal Cell Carcinoma Segment to Account for Major Share of Global Market
5/6/2021
Hedgehog proteins consist of a group of proteins that regulate cell differentiation, growth, and survival. These proteins are involved in organogenesis and have shown to promote adult stem cell proliferation.